Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126826202 | 12682620 | 2 | F | 20160810 | 20160825 | 20160825 | EXP | US-CIPLA LTD.-2016US17565 | CIPLA | PORSTEINSSON AP, DRYE LT, POLLOCK BG, DEVANAND DP, FRANGAKIS C, ISMAIL Z, ET AL. EFFECT OF CITALOPRAM ON AGITATION IN ALZHEIMER^S DISEASE-THE CITAD RANDOMIZED CONTROLLED TRIAL. JAMA. 2014;311 (7):682 TO 691 | 0.00 | Y | 0.00000 | 20160825 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126826202 | 12682620 | 1 | PS | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | Unknown | 10 MG,QD | U | U | 0 | 10 | MG | CAPSULE | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126826202 | 12682620 | 1 | Agitation |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126826202 | 12682620 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126826202 | 12682620 | Agitation | |
| 126826202 | 12682620 | Fall | |
| 126826202 | 12682620 | Syncope |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |